Bluebird Bio’s Lovo-Cel For Sickle Cell Disease Finally Under FDA Review

Sickle Cell
Bluebird Bio1 submits application to FDA for gene therapy lovo-cel for approval to treat people aged 12+ with sickle cell disease

Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: